34 related articles for article (PubMed ID: 3310628)
1. ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats.
Marks SL; Kook PH; Papich MG; Tolbert MK; Willard MD
J Vet Intern Med; 2018 Nov; 32(6):1823-1840. PubMed ID: 30378711
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions.
Mermelstein J; Chait Mermelstein A; Chait MM
Clin Exp Gastroenterol; 2018; 11():119-134. PubMed ID: 29606884
[TBL] [Abstract][Full Text] [Related]
3. The Proton Pump Inhibitor Non-Responder: A Clinical Conundrum.
Hussain ZH; Henderson EE; Maradey-Romerao C; George N; Fass R; Lacy BE
Clin Transl Gastroenterol; 2015 Aug; 6(8):e106. PubMed ID: 26270485
[TBL] [Abstract][Full Text] [Related]
4. Current pharmacological management of gastroesophageal reflux disease.
Wang YK; Hsu WH; Wang SS; Lu CY; Kuo FC; Su YC; Yang SF; Chen CY; Wu DC; Kuo CH
Gastroenterol Res Pract; 2013; 2013():983653. PubMed ID: 23878534
[TBL] [Abstract][Full Text] [Related]
5. Meta-Analyses of Cisapride, Omeprazole and Ranitidine in the Treatment of GORD: Implications for Treating Patient Subgroups.
Iskedjian M; Einarson TR
Clin Drug Investig; 1998; 16(1):9-18. PubMed ID: 18370513
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials.
Sharma N; Donnellan C; Preston C; Delaney B; Duckett G; Moayyedi P
Gut; 2004 May; 53 Suppl 4(Suppl 4):iv58-65. PubMed ID: 15082617
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological management of gastro-oesophageal reflux disease.
Klinkenberg-Knol EC; Festen HP; Meuwissen SG
Drugs; 1995 May; 49(5):695-710. PubMed ID: 7601011
[TBL] [Abstract][Full Text] [Related]
8. Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.
Grant SM; Langtry HD; Brogden RN
Drugs; 1989 Jun; 37(6):801-70. PubMed ID: 2667937
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of sucralfate in reflux oesophagitis.
Tytgat GN
Scand J Gastroenterol Suppl; 1987; 140():29-31. PubMed ID: 3328282
[TBL] [Abstract][Full Text] [Related]
10. Role of sucralfate in peptic disease.
Jensen SL; Funch Jensen P
Dig Dis; 1992; 10(3):153-61. PubMed ID: 1611711
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effect of sucralfate and ranitidine in reflux esophagitis.
Simon B; Mueller P
Am J Med; 1987 Sep; 83(3B):43-7. PubMed ID: 3310628
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the clinical efficacy of ranitidine and sucralfate in reflux esophagitis.
Chopra BK; Kazal HL; Mittal PK; Sibia SS
J Assoc Physicians India; 1992 Jul; 40(7):439-41. PubMed ID: 1484022
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy of sucralfate and ranitidine, compared with sucralfate monotherapy, in patients with peptic reflux esophagitis.
Vermeijden JR; Tytgat GN; Schotborgh RH; Dekker W; vd Boomgaard DM; van Olffen GH; Schrijver M; Vosmaer GD; Dekkers CP
Scand J Gastroenterol; 1992; 27(2):81-4. PubMed ID: 1561531
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the clinical efficacy of ranitidine and sucralfate in reflux oesophagitis.
Chopra BK; Kazal HL; Mittal PK; Sibia SS
J Assoc Physicians India; 1992 Mar; 40(3):162-3. PubMed ID: 1634480
[TBL] [Abstract][Full Text] [Related]
15. Sucralfate in the treatment of reflux esophagitis in adults: an update.
Simon B; Dammann HG; Müller P
Scand J Gastroenterol Suppl; 1989; 156():37-41. PubMed ID: 2662389
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
